Accepted at 1:45 a.m. Feb, 12, 2024 by herstein.jacob
Author: cohenalexajo
Related Note: 1547252140514 2
Rationale for change

Dimercaprol and EDTA are not necessarily first-line of treatment. For mild lead toxicity (5-44 µg/dL), medication is not indicated. Moderate lead toxicity (55-69 µg/dL) is treated with DMSA chelation therapy. Only severe lead toxicity (≥70 µg/dL) warrants treatment with Dimercaprol and EDTA.
Source: UWorld - Step 3 10017

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Empty field
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
OME
Additional Resources
Empty field
One by one
#AK_Other::Card_Features::Mnemonic #PANCE::HEME::cytopenias #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::RBC_Misc. #AK_Step1_v12::#UWorld::Step::1865 #AK_Step1_v12::^Other::^FA_Updates::FA2019 #AK_Other::Card_Features::^One_By_One #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::03_Microcytic_Anemia::05_Lead_Toxicity #AK_Step1_v12::#FirstAid::05_Pharm::03_Toxicities_and_Adverse_Effects::03_Specific_toxicity_treatments #PANCE::EOR::PEDS #AK_Step3_v12::#UWorld::5663 #AK_Step2_v12::#AMBOSS::GG0B03 #AK_Step2_v12::#UWorld::Step::12396 #AK_Step1_v12::#OME::Clinical::04_Organ_Systems::05_Hematology_Oncology::02_Anemia::02_Disorders_of_Heme_synthesis #AK_Step1_v12::#NBME::21 #AK_Step1_v12::#OME::04_Organ_Systems::05_Hematology_Oncology::02_Anemia::02_Disorders_of_Heme_synthesis #AK_Other::!AK_UpdateTags::AnKing_Image::NikolausClodi #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#B&B::12_Hematology::02_Red_Blood_Cells::04_Microcytic_Anemias::Extra #AK_Step1_v12::#AMBOSS::#Self_Assessment #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::14_Heme_synthesis_porphyrias_and_lead_poisoning::*Lead_Poisoning #AK_Step1_v12::#UWorld::COMLEX::24974 #AK_Step1_v12::#UWorld::Step::1156 #AK_Step2_v12::#UWorld::#UWSA2 #AK_Step2_v12::#UWorld::Step::12039 #AK_Step3_v12::#UWorld::6269 #AK_Step1_v12::^Systems::HemeOnc::RBC::MiscAdds #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::07_Microcytic_hypochromic_anemias::04_Lead_poisoning #AK_Step1_v12::#UWorld::COMLEX::24267 #AK_Step2_v12::#AMBOSS #AK_Step1_v12::#AMBOSS::eaaxjQ